Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study

Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study

BackgroundIndividuals with schizophrenia have substantially elevated cardiovascular morbidity and mortality, a disparity further exacerbated by coexisting type 2 diabetes mellitus (T2DM). The impact of specific antipsychotics on long-term cardiovascular outcomes in patients with T2DM remains unclear...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yi-Ting Yeh, Shih-Chang Lo, Chien-Ning Huang, Yi-Sun Yang, Pei-Lun Liao, Edy Kornelius
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	aripiprazole risperidone MACE schizophrenia diabetes
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1617534/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

The maintenance of modified electroconvulsive therapy combined with risperidone is better than risperidone alone in preventing relapse of schizophrenia and improving cognitive function
by: Ying Yang, et al.

Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
by: Sanya Sharma, et al.
Published: (2023-10-01)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
by: Kishi T, et al.
Published: (2016-11-01)

Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
by: Zhen Mao, et al.
Published: (2024-12-01)

A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia
by: Tianbao Wei, et al.
Published: (2025-01-01)

Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-10-01)

Anxiety disorders in patients with thyroid nodules vs. thyroid cancer: a retrospective cohort study
by: Edy Kornelius, et al.
Published: (2025-04-01)

Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review
by: Ana Carrascosa-Arteaga, et al.
Published: (2025-05-01)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
by: Peters-Strickland T, et al.
Published: (2016-10-01)

MRI-based insights into brain structural and functional alterations in schizophrenia treated with risperidone
by: Hangyu Li, et al.
Published: (2025-06-01)

Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
by: Yin Cao, et al.
Published: (2024-12-01)

Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study
by: En-Wei Chang, et al.
Published: (2025-06-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Antipsychotic medication for behaviors that challenge in individuals with intellectual disabilities: a clinically informed review
by: Alessandro Pascucci, et al.
Published: (2025-07-01)

Activation of osteoblast ferroptosis by risperidone accelerates bone loss in mice models of schizophrenia
by: Hongyan Fan, et al.
Published: (2025-01-01)

Risperidone-induced Myoclonus in a Young Patient with Schizophrenia
by: Aman Naqvi, et al.
Published: (2025-01-01)

Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
by: A. R. Asadullin, et al.
Published: (2025-06-01)

Flash Chromatography Application for Risperidone Purification
by: G. S. Trush, et al.
Published: (2015-08-01)

Clinical Effectiveness of Aripiprazole in Short-term Treatment of Tic Disorder in Children and Adolescents: A Naturalistic Study
by: Che-Sheng Ho, et al.
Published: (2014-02-01)

Histological and Biochemical Changes in Ovaries of Adult Wistar Rats Following Exposure to Risperidone
by: Onyilo, P.O.*, Dirisu, E.I., Samuel, B.O.
Published: (2024-11-01)

Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
by: E. G. Kornetova, et al.
Published: (2018-12-01)

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas
by: Edward Mignone, et al.
Published: (2025-01-01)

A cross-sectional study to analyze the pattern of pharmacotherapy and its associated factors among patients with schizophrenia
by: B. S. Abhishree, et al.
Published: (2024-12-01)

Neuropeptide Y in first-episode schizophrenia: is there any sex differences in the pathogeneses of schizophrenia?
by: Jia-Qi Song, et al.
Published: (2024-12-01)

Otizm ve tourette sendromu birlikteliğinde düşük doz aripiprazol monoterapisinin etkinliği: olgu sunumu
by: Necati Uzun
Published: (2018-01-01)

Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
by: Jerson Laks, et al.
Published: (2001-12-01)

METHODS ELABORATION ON DETECTION OF SOME ATYPICAL NEUROLYTIC AGENTS FOR CHEMICAL AND TOXICOLOGICAL ANALYSIS
by: I. P. Remezova, et al.
Published: (2015-09-01)

Unusual Weight Loss in a Schizophrenic Patient Following Treatment With Aripiprazole: A Case Report
by: Amir Asadi, et al.
Published: (2025-03-01)

Risperidone-induced Premature Ventricular Complexes in Psychosis: A Case Report
by: Javed A Siddiqui, et al.
Published: (2023-06-01)

Agar/β-Cyclodextrin Composite Cryogels for Controlled Release of Aripiprazole
by: Siyka Stoilova, et al.
Published: (2025-02-01)

Exploring the efficacy and tolerability of two‐injection start regimen of long‐acting aripiprazole: A descriptive case series analysis
by: Ibrahim Sungur, et al.
Published: (2024-12-01)

Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone
by: Rathi R, et al.
Published: (2024-11-01)

An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans
by: Lilach Steiner, et al.
Published: (2025-01-01)

Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state
by: Han-Jung Liu, et al.
Published: (2025-07-01)

Association of herpes zoster vaccination and cardiovascular risk in patients with diabetes: long-term insights from a retrospective cohort study
by: Yu-Hsun Wang, et al.
Published: (2025-02-01)

An Approach to Enhance the Solubility of an Atypical Antipsychotic Drug, Aripiprazole: Design, Characterization, and Evaluation of Arabinoxylan-Based Nanoparticles
by: Sikander M, et al.
Published: (2025-02-01)

Evaluation of the combined effect of aripiprazole and sertraline in the treatment of obsessive-compulsive disorder in adolescents
by: Fatemeh Assarian, et al.
Published: (2024-12-01)

Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies
by: Bartoli F, et al.
Published: (2025-06-01)

Advanced LC-MS/MS method for selective quantification of nitrosamine impurities in Risperidone: Enhancing drug safety
by: Hitesh Thumbar, et al.
Published: (2025-08-01)